Unity Biotechnology, Inc. Proceeds from Convertible Debt
Unity Biotechnology, Inc. reported Proceeds from Convertible Debt of $16.89 million for the 12-month period ending 2016-12-31, per its 10-K filed 2019-03-06.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromConvertibleDebt · last filed 2019-03-06
- Unity Biotechnology, Inc. proceeds from convertible debt for fiscal 2016 was $16.89M.
| Period end | Proceeds from Convertible Debt 12 month |
|---|---|
| 2016-12-31 | $16.89M 10-K · filed 2019-03-06 |